Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab Q6W.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04875195
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 7, 2021
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Terminated NCT03776864 - Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Terminated NCT01699581 - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant Phase 2
Completed NCT00784537 - High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients Phase 2/Phase 3
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT05355051 - A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Phase 2
Completed NCT00520130 - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase 1/Phase 2
Withdrawn NCT01316146 - Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) Phase 1
Completed NCT02223052 - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Phase 1
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT01745913 - Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies Phase 2
Recruiting NCT04665063 - A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma N/A
Recruiting NCT02259556 - CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas Phase 1/Phase 2
Completed NCT02003625 - Meloxicam vs Placebo for Mobilization Phase 2
Terminated NCT01742793 - An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) Phase 1
Completed NCT01402687 - SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) N/A
Terminated NCT00901303 - Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma N/A
Completed NCT00283439 - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Phase 1/Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A